Association between P2RY12 Gene Polymorphisms and IVIG Resistance in Kawasaki Patients

Zhouping Wang1, Yufen Xu2, Huazhong Zhou2

  • 1Department of Cardiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, China.

Insights

Kawasaki disease (KD) patients with a specific P2RY12 gene variation (rs6809699) show reduced resistance to intravenous immunoglobulin (IVIG) treatment. This finding suggests P2RY12 rs6809699 may serve as a biomarker for predicting IVIG resistance in KD.

Area of Science:

  • Genetics
  • Immunology
  • Pediatrics

Background:

  • Kawasaki disease (KD) is a critical condition in children, with intravenous immunoglobulin (IVIG) resistance linked to coronary artery lesions (CAL).
  • Purinergic receptor P2Y12 (P2RY12) polymorphisms are associated with KD genetic susceptibility and CAL, but their role in IVIG resistance remains understudied.

Purpose of the Study:

  • To investigate the association between P2RY12 polymorphisms and IVIG resistance in Kawasaki disease patients.
  • To identify potential genetic biomarkers for predicting IVIG resistance in KD.

Main Methods:

  • A case-control study involving 148 IVIG-resistant and 611 IVIG-sensitive KD patients.
  • Genotyping of five P2RY12 polymorphisms (rs9859538, rs1491974, rs7637803, rs6809699, rs2046934).
  • Statistical analysis, including odds ratios (OR) and confidence intervals (CI), adjusted for age and gender.

Main Results:

  • The P2RY12 rs6809699 A>C polymorphism showed a significant association with IVIG sensitivity (e.g., AC vs. AA: adjusted OR=0.48, P=0.011).
  • Carriers of the rs6809699 C allele exhibited a protective effect against IVIG resistance (adjusted OR=0.44-0.49).
  • Individuals with all five identified protective polymorphisms had significantly decreased IVIG resistance (adjusted OR=0.27, P=0.0006).

Conclusions:

  • The P2RY12 rs6809699 polymorphism may act as a predictive biomarker for IVIG resistance in Kawasaki disease patients.
  • Identifying patients with specific P2RY12 genotypes could aid in tailoring treatment strategies and managing KD complications.